Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Allogene Therapeutics, Inc.

< Previous 1 2 Next >
Allogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal Cell Carcinoma
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
Allogene Therapeutics Announces Q2 Investor Conference Participation
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
Allogene Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
Allogene Therapeutics and Arbor Biotechnologies Announce Global Gene Editing Licensing Agreement to Support Advancement of Next-Generation Allogeneic CAR T Platform in Autoimmune Disease
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
Allogene Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
Allogene Therapeutics Announces Participation in the 44th Annual TD Cowen Health Care Conference
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
Allogene Therapeutics to Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting Adjustments Related to the December 2020 Formation of the Allogene Overland Biopharm Joint Venture in Asia
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
Allogene Therapeutics Announces 2024 Platform Vision to Redefine the Future of CAR T Led by ALPHA3, the Industry's First Pivotal Trial for Frontline Consolidation in Large B-Cell Lymphoma
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
Allogene Therapeutics to Host Conference Call Previewing its 2024 Platform Vision and Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
Allogene Therapeutics Presents Comprehensive Safety Data of Proprietary Lymphodepletion Agent ALLO-647 at the 65th Annual Meeting of the American Society of Hematology
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
Allogene Therapeutics Announces Participation in December Investor Conference
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
Allogene Therapeutics Presents Preclinical Data on a Novel Allogeneic CAR T Product Candidate Targeting Claudin18.2 at the Society for Immunotherapy of Cancer Annual Meeting
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
Allogene Therapeutics Presents Preclinical Data on Next Generation Cloak™ and Dagger™ Technologies at the Society for Immunotherapy of Cancer Annual Meeting
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
Allogene Therapeutics Reports Third Quarter 2023 Financial Results and Business Update
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
Allogene Therapeutics Announces Poster Presentations at the 65th Annual Meeting of the American Society of Hematology
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
Allogene Therapeutics Announces Participation in November Investor Conferences
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
Allogene Therapeutics to Report Third Quarter 2023 Financial Results on November 2, 2023
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
Allogene Therapeutics Appoints Geoffrey Parker as Chief Financial Officer
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
Allogene Therapeutics Announces Three Poster Presentations from its Next Generation AlloCAR T™ Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
Allogene Therapeutics Announces Participation in September Investor Conference
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
Allogene Therapeutics Appoints Earl Douglas as General Counsel
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
Allogene Therapeutics Reports Second Quarter 2023 Financial Results and Business Update
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
Allogene Therapeutics to Report Second Quarter 2023 Financial Results on August 2, 2023
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
Allogene Therapeutics Provides Additional ALLO-501/501A Phase 1 Data in an Oral Presentation at the International Conference on Malignant Lymphoma (ICML) Lugano
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
Allogene Therapeutics Announces Departure of Chief Financial Officer
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
Allogene Therapeutics Announces Oral Presentation of Phase 1 Data on ALLO-501/501A in Large B Cell Lymphoma at the International Conference on Malignant Lymphoma (ICML) Lugano
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
Allogene Therapeutics Presents Updated ALLO-501/501A Phase 1 Data in Large B Cell Lymphoma at the American Society of Clinical Oncology (ASCO) Annual Meeting
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
Allogene Therapeutics Announces Participation in Three Upcoming Investor Conferences
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
Allogene Therapeutics Announces Encore Presentation of Phase 1 Data from the ALLO-501/501A Trials in Large B Cell Lymphoma at the European Hematology Association (EHA) Hybrid Congress
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS